McKesson (MCK) Q3 2026 Earnings Review: specialty-drug growth lifts the profit outlook

Q2 2027 earnings recap

McKesson raised its full-year profit outlook as specialty-drug distribution and oncology services expanded, strengthening the case for its shift toward more specialized healthcare services.

• Fiscal Q2 2027 adjusted profit per share reached $11.68 versus $10.72 expected, while revenue rose 8% to $111 billion and beat the roughly $109.9 billion forecast.
• Oncology and multispecialty revenue grew 24%, helping offset weaker medical-surgical profitability and lifting the fiscal 2027 adjusted profit target to $45.6–$46.4 per share.
• First-half free cash flow of about $2.6 billion trailed $3.6 billion returned to shareholders, making the balance between buybacks, acquisitions and financial flexibility worth watching.
• McKesson completed its Precision Medicine Group acquisition on November 2, while its planned $1.4 billion investment for a 49% Option Care Health stake still requires approvals.
• The November 4 close represented about 27.6 times trailing reported profit, so sustained specialty growth matters more than the company’s large but low-margin distribution sales.
• Shares rose 7.0% during the regular session before results, then traded about 0.9% below that close afterward, with the regular close above both the 20-day and 50-day averages.

Watch acquisition integration and medical-surgical margins, because lower reimbursement, an unfavorable product mix or weaker cash conversion could reduce the benefit of higher prescription volumes.